This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Incyte's (INCY) Itacitinib Fails in Late-Stage GVHD Study
by Zacks Equity Research
Incyte (INCY) fails to meet goals in the phase III study on itacitinib for the treatment of first-line acute GVHD.
Glaxo (GSK) Shares Continue to Witness Upside: Here's Why
by Zacks Equity Research
Glaxo's (GSK) successful product launches, increasing focus on the oncology area, and positive pipeline and regulatory updates are driving the stock.
Global Blood (GBT) Shares Double in a Year, Focus on Oxbryta
by Zacks Equity Research
Shares of Global Blood Therapeutics (GBT) have gained in the past year as its lead candidate voxelotor gets FDA approval for the treatment of SCD in patients aged 12 years or above.
3 Biotech Stocks Likely to Maintain Solid Momentum in 2020
by Ekta Bagri
With the biotech sector gaining steam in recent times, we shortlist three biotech stocks that are set to maintain momentum in 2020.
Epizyme (EPZM) Shares Soar on Lead Candidate's Progress
by Zacks Equity Research
Epizyme's (EPZM) shares soar year to date on positive developments for its lead pipeline candidate tazemetostat being evaluated for the treatment of solid tumors and hematological malignancies
Incyte (INCY) Surges 44% YTD on Jakafi's Strong Performance
by Zacks Equity Research
Incyte (INCY) outperforms the industry year to date on strong Jakafi sales.
Biotech Leading in Q4: Best ETFs & Stocks
by Sweta Killa
We highlight five biotech ETFs and stocks that are leading the market in Q4.
Allergan (AGN) Gets FDA Approval for Migraine Drug Ubrelvy
by Zacks Equity Research
Allergan (AGN) gets FDA nod for Ubrelvy for the acute treatment of migraine with or without aura in adults.
Pharma Stock Roundup: Lilly's Upbeat 2020 Outlook, FDA Nod for PFE & MRK's Drugs
by Kinjel Shah
Lilly (LLY) issues upbeat financial guidance for 2020. FDA approves label expansion of Pfizer's (PFE) Xtandi and Merck's (MRK) Ebola vaccine, Ervebo.
AbbVie's JAK Inhibitor Rinvoq Receives Approval for RA in EU
by Zacks Equity Research
AbbVie's (ABBV) oral JAK inhibitor, upadacitinib, receives approval in Europe for treating rheumatoid arthritis under the trade name of Rinvoq.
Novartis' Asthma Candidate Fails in LUSTER Phase III Studies
by Zacks Equity Research
Novartis' (NVS) asthma candidate, fevipiprant, fails to meet endpoint in the phase III LUSTER studies.
Novartis Gets Positive CHMP Opinion for Wet AMD Drug Beovu
by Zacks Equity Research
Novartis (NVS) obtains positive CHMP opinion for its wet AMD drug Beovu. A potential approval will boost its ophthalmology franchise.
Novartis (NVS) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Novartis (NVS) closed the most recent trading day at $93.06, moving +0.02% from the previous trading session.
The Zacks Analyst Blog Highlights: Novartis, AbbVie, Sanofi, Pioneer Natural Resources and Aqua America
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Novartis, AbbVie, Sanofi, Pioneer Natural Resources and Aqua America
Gilead Teams Up With Kiniksa, Submits BLA for CAR T Therapy
by Zacks Equity Research
Gilead (GILD) collaborates with Kiniksa for a combination study and submits BLA for CAR T therapy candidate.
Roche's (RHHBY) sBLA for Asthma Drug Xolair Accepted by FDA
by Zacks Equity Research
The FDA accepts Roche's (RHHBY) allergic asthma drug Xolair's sBLA for the treatment of nasal polyps in adult patients aged 18 years or above with inadequate response to intranasal corticosteroids.
Top Research Reports for Novartis, AbbVie & Sanofi
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Novartis (NVS), AbbVie (ABBV) and Sanofi (SNY).
Why Biotech ETFs are Surging to New Highs
by Neena Mishra
increasing M&A deals and cutting edge therapies are driving biotech ETFs higher
Sanofi Unveils Growth Strategy, Ends Diabetes & CV Research
by Zacks Equity Research
Sanofi (SNY) to prioritize key growth drivers, improve operating efficiencies and generate cost savings. The company discontinues R&D activities in diabetes and cardiovascular segments.
Gilead (GILD) Announces Positive Long-Term Data on Yescarta
by Zacks Equity Research
Gilead (GILD) announces positive long-term data from a mid-stage study on Yescarta in adult patients with refractory large B-cell lymphoma.
Biogen Up on New Data on Alzheimer's Candidate Aducanumab
by Zacks Equity Research
Biogen (BIIB) divulges new positive data on Alzheimer's candidate, aducanumab at CTAD. Stock rises.
Regeneron Reports Positive Data on Rare Blood Disorder Drug
by Zacks Equity Research
Regeneron (REGN) announces positive top-line data from a phase II study on rare blood disorder drug.
Novartis (NVS) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Novartis (NVS) closed at $91.64 in the latest trading session, marking a +0.09% move from the prior day.
Axsome Narcolepsy Candidate Meets Phase II Goal, Stock Up
by Zacks Equity Research
Axsome (AXSM) announces data from a phase II study evaluating AXS-12 in narcolepsy patients, demonstrating statistically significant reduction in weekly cataplexy attacks.
Biogen's Shares Down on Rating Downgrade by Baird Analyst
by Zacks Equity Research
Biogen's (BIIB) shares decline following a rating downgrade by an analyst at Robert W. Baird on concerns related to approval of Alzheimer's disease candidate, aducanumab.